Treatment of Cushing Disease With Pituitary-Targeting Seliciclib
The Journal of Clinical Endocrinology & Metabolism · 15.02.2023 · 108 (3) · 726-735
DOI: 10.1210/clinem/dgac588 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 10.10.2022. Verfasst von Ning-Ai Liu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Pituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Hauptthemen laut MEDLINE: Pituitary ACTH Hypersecretion. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: FDA HHS, NIDDK NIH HHS, NIDDK.
Abstract (Originalsprache)
Context
Preclinical studies show seliciclib (R-roscovitine) suppresses neoplastic corticotroph proliferation and pituitary adrenocorticotrophic hormone (ACTH) production.
Objective
To evaluate seliciclib as an effective pituitary-targeting treatment for patients with Cushing disease (CD).
Methods
Two prospective, open-label, phase 2 trials, conducted at a tertiary referral pituitary center, included adult patients with de novo, persistent, or recurrent CD who received oral seliciclib 400 mg twice daily for 4 consecutive days each week for 4 weeks. The primary endpoint in the proof-of-concept single-center study was normalization of 24-hour urinary free cortisol (UFC; ≤ 50 µg/24 hours) at study end; in the pilot multicenter study, primary endpoint was UFC normalization or ≥ 50% reduction in UFC from baseline to study end.
Results
Sixteen patients were consented and 9 were treated. Mean UFC decreased by 42%, from 226.4 ± 140.3 µg/24 hours at baseline to 131.3 ± 114.3 µg/24 hours by study end. Longitudinal model showed significant UFC reductions from baseline to each treatment week. Three patients achieved ≥ 50% UFC reduction (range, 55%-75%), and 2 patients exhibited 48% reduction; none achieved UFC normalization. Plasma ACTH decreased by 19% (P = 0.01) in patients who achieved ≥ 48% UFC reduction. Three patients developed grade ≤ 2 elevated liver enzymes, anemia, and/or elevated creatinine, which resolved with dose interruption/reduction. Two patients developed grade 4 liver-related serious adverse events that resolved within 4 weeks of seliciclib discontinuation.
Conclusion
Seliciclib may directly target pituitary corticotrophs in CD and reverse hypercortisolism. Potential liver toxicity of seliciclib resolves with treatment withdrawal. The lowest effective dose requires further determination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
- Pituitary Center, Department of Medicine, Keck School of Medicine of University of Southern California, Los Angeles, CA 90033, USA.
- Department of Medicine, The Lundquist Institute and Harbor-UCLA Medical Center, Torrance, CA 90509, USA.
- Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90024, USA.
- Pacific Neuroscience Institute, Providence Saint John's Health Center, Santa Monica, CA 90404, USA.
- Karsh Division of Gastroenterology and Hepatology, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
ORCID-Profile: Shlomo Melmed
Förderung
- FDA HHS
- NIDDK NIH HHS
- NIDDK
- U.S. Food and Drug Administration
- National Institutes of Health
Zitieren
APA
Liu, N. A., Ben-Shlomo, A., Carmichael, J. D., Wang, C., Swerdloff, R. S., Heaney, A. P., Barkhoudarian, G., Kelly, D., Noureddin, M., Lu, L., Desai, M., Stolyarov, Y., Yuen, K., Mamelak, A. N., Mirocha, J., Tighiouart, M., & Melmed, S. (2023). Treatment of Cushing Disease With Pituitary-Targeting Seliciclib. The Journal of Clinical Endocrinology & Metabolism, 108(3), 726-735. https://doi.org/10.1210/clinem/dgac588
Vancouver
Liu NA, Ben-Shlomo A, Carmichael JD, Wang C, Swerdloff RS, Heaney AP, et al. Treatment of Cushing Disease With Pituitary-Targeting Seliciclib. The Journal of Clinical Endocrinology & Metabolism. 2023;108(3):726-735. doi:10.1210/clinem/dgac588
BibTeX
@article{Liu2023,
author = {Liu, Ning-Ai and Ben-Shlomo, Anat and Carmichael, John D and Wang, Christina and Swerdloff, Ronald S and Heaney, Anthony P and Barkhoudarian, Garni and Kelly, Daniel and Noureddin, Mazen and Lu, Lin and Desai, Manish and Stolyarov, Yana and Yuen, Kevin and Mamelak, Adam N and Mirocha, James and Tighiouart, Mourad and Melmed, Shlomo},
title = {Treatment of Cushing Disease With Pituitary-Targeting Seliciclib},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
volume = {108},
number = {3},
pages = {726--735},
doi = {10.1210/clinem/dgac588}
}
EUVIMED